Head and Neck Cancers
Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC
February 25, 2021
Article
The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.
Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers
August 13, 2020
Article
Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
FDA Expands Gardasil 9 Approval for HPV-Related Cancers
June 15, 2020
Article
On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.
Expert Discusses Updates in Thyroid Cancer
November 23, 2019
Video
The past 10 years have shown significant updates for treatment of patients with thyroid cancer, beyond just targeted therapies.
FDA Approves Pembrolizumab for Esophageal Cancer Subgroup
July 31, 2019
Article
The FDA approved pembrolizumab to treat certain patients with recurrent, locally advanced or metastatic squamous cell carcinoma of the esophagus.
Oncology Nurses Are Key in Head and Neck Cancer Care
June 20, 2019
Video
Nurses are there for patients every step of the way.
FDA Approves Pembrolizumab Regimens for HNSCC
June 11, 2019
Article
The FDA approved pembrolizumab alone or in combination with 5-FU to treat recurrent or metastatic head and neck squamous cell carcinoma.
Eliminating Gender-Based Barriers to Immunotherapy
May 29, 2019
Article
Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.
Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer
May 16, 2019
Article
A group of researchers in the UK sought out to determine the efficacy of a reduced-dose regimen of oxaliplatin (Eloxatin) and capecitabine (Xeloda) in this patient population through the randomized, phase III GO2 clinical trial.
Twitter Lends Insight to HPV-Associated Oral Cancer Knowledge
May 01, 2019
Article
The HPV vaccine is commonly associated with preventing cervical cancer, but it plays a major role in oral cancers, too.